GILD241227C92000
- 2.05
- 0.000.00%
Gilead Sciences Newsroom
Jefferies Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $115
Morgan Stanley Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $113
Citi Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $125
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Gilead Sciences (GILD) and Abbott Laboratories (ABT)
Gilead Sciences: Supreme Court Case and New Innovations Drive Buy Rating
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Bernstein Sticks to Its Buy Rating for Gilead Sciences (GILD)
Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating
Gilead Sciences Analyst Ratings
Morgan Stanley Upgrades Gilead Sciences(GILD.US) to Buy Rating, Raises Target Price to $113
Gilead Sciences: Buy Rating Backed by Promising Pipeline and Attractive Valuation
RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating
Gilead Sciences' Buy Rating Affirmed on HIV Market Potential and Strategic Leadership Changes
Bernstein Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
Truist Financial Maintains Gilead Sciences(GILD.US) With Hold Rating
Gilead Sciences (GILD) Gets a Hold From Truist Financial
Piper Sandler Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $105
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $99 to $115
Gilead Sciences (GILD) Gets a Buy From Piper Sandler
Gilead Sciences Price Target Maintained With a $80.00/Share by Cantor Fitzgerald